<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="UTF-8">
  <meta name="viewport" content="width=device-width, initial-scale=1.0">
  <title>From &quot;Synapse&quot; to &quot;Overfitted&quot;! - Hex Index</title>
  <link rel="stylesheet" href="../../styles.css">
</head>
<body class="reading-mode">
  <header class="reading-header">
    <a href="../../index.html" class="back-link">&larr; Back to Library</a>
  </header>
  <main class="reading-content">
    
    <article class="article-page">
      <header class="article-header">
        <h1>From &quot;Synapse&quot; to &quot;Overfitted&quot;!</h1>
        <div class="article-meta">
          <span class="author">By Clayton</span>
          <span class="separator">&middot;</span>
          <a href="../../publication/synapse/index.html" class="publication">
            Synapse
          </a>
          <span class="separator">&middot;</span><time>Aug 20, 2025</time>
          <span class="separator">&middot;</span>
          <span class="read-time">3 min read</span>
        </div>
      </header>

      

      <div class="article-excerpt">
        <p>Hey <em>Synapse </em>readers! </p><p>I’ve launched a new newsletter called <strong><a href="https://overfittedtoday.substack.com">Overfitted</a></strong>, my attempt to cut through the noise in evidence-based medicine. We’ll dissect studies, challenge assumptions, and debate ideas—mostly in Neurology and Alzheimer’s, though not exclusively. If that sounds interesting, subscribe (it’s free):</p><p><em>Synapse</em> was a fun pandemic project on neuroscience, from free will to morality. Since then, I’ve started an MD/PhD and my focus has shifted toward clinical neurology. <a href="https://rdcu.be/eBBCS">Writing is thinking</a>, and I’ve missed the conversation. <em>Overfitted</em> is my way back—and a push for more common sense in biomedicine.</p><p>To give you a taste, I’ve pasted the first post below. Enjoy!</p><div><hr></div><h1>Current AD Blood Biomarker Studies Miss What's Most Important</h1><p><em>What are we optimizing for?</em></p><p>In case you haven’t heard, there are new blood-based assays for Alzheimer’s Disease that detect amyloid and tau in the brain without requiring a brain scan or spinal tap. They are a technical achievement, <a href="https://jamanetwork.com/journals/jamaneurology/fullarticle/2813751">showing strong correlations</a> with what is going on in the brain. </p><p>In my mind, the main advantage of blood biomarkers for AD is that they are less expensive and invasive and are accessible in the primary care setting just like any other blood test. They <em>could</em>, therefore, be revolutionary for Alzheimer’s Disease treatment and care. </p><p>So what’s the problem? </p><p>We have no idea if they make a difference in outcomes that actually matter to patients. </p><p>Willem A Van Gool and colleagues just <a href="https://doi.org/10.1136/bmj-2025-084781">published an excellent review</a> in the BMJ of current AD blood biomarker studies that reveal that nearly every study to date focus on technical and “diagnostic” accuracy without looking at whether patient outcomes are any better.</p><div class="captioned-image-container"><figure><a class="image-link image2 is-viewable-img" target="_blank" href="https://substackcdn.com/image/fetch/$s_!W-17!,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fff41c9c9-4016-4ce8-83e4-9e2d3330f6b8_1057x771.jpeg" data-component-name="Image2ToDOM"><div class="image2-inset"><picture><source type="image/webp" srcset="https://substackcdn.com/image/fetch/$s_!W-17!,w_424,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fff41c9c9-4016-4ce8-83e4-9e2d3330f6b8_1057x771.jpeg 424w, https://substackcdn.com/image/fetch/$s_!W-17!,w_848,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fff41c9c9-4016-4ce8-83e4-9e2d3330f6b8_1057x771.jpeg 848w, https://substackcdn.com/image/fetch/$s_!W-17!,w_1272,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fff41c9c9-4016-4ce8-83e4-9e2d3330f6b8_1057x771.jpeg 1272w, https://substackcdn.com/image/fetch/$s_!W-17!,w_1456,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fff41c9c9-4016-4ce8-83e4-9e2d3330f6b8_1057x771.jpeg 1456w" sizes="100vw"><img src="https://substackcdn.com/image/fetch/$s_!W-17!,w_1456,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fff41c9c9-4016-4ce8-83e4-9e2d3330f6b8_1057x771.jpeg" width="1057" height="771" data-attrs="{&quot;src&quot;:&quot;https://substack-post-media.s3.amazonaws.com/public/images/ff41c9c9-4016-4ce8-83e4-9e2d3330f6b8_1057x771.jpeg&quot;,&quot;srcNoWatermark&quot;:null,&quot;fullscreen&quot;:null,&quot;imageSize&quot;:null,&quot;height&quot;:771,&quot;width&quot;:1057,&quot;resizeWidth&quot;:null,&quot;bytes&quot;:169518,&quot;alt&quot;:&quot;&quot;,&quot;title&quot;:null,&quot;type&quot;:&quot;image/jpeg&quot;,&quot;href&quot;:null,&quot;belowTheFold&quot;:true,&quot;topImage&quot;:false,&quot;internalRedirect&quot;:&quot;https://overfittedtoday.substack.com/i/170687263?img=https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fff41c9c9-4016-4ce8-83e4-9e2d3330f6b8_1057x771.jpeg&quot;,&quot;isProcessing&quot;:false,&quot;align&quot;:null,&quot;offset&quot;:false}" class="sizing-normal" alt="" title="" srcset="https://substackcdn.com/image/fetch/$s_!W-17!,w_424,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fff41c9c9-4016-4ce8-83e4-9e2d3330f6b8_1057x771.jpeg 424w, https://substackcdn.com/image/fetch/$s_!W-17!,w_848,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fff41c9c9-4016-4ce8-83e4-9e2d3330f6b8_1057x771.jpeg 848w, https://substackcdn.com/image/fetch/$s_!W-17!,w_1272,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fff41c9c9-4016-4ce8-83e4-9e2d3330f6b8_1057x771.jpeg 1272w, https://substackcdn.com/image/fetch/$s_!W-17!,w_1456,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fff41c9c9-4016-4ce8-83e4-9e2d3330f6b8_1057x771.jpeg 1456w" sizes="100vw" loading="lazy"></picture><div class="image-link-expand"><div class="pencraft pc-display-flex pc-gap-8 pc-reset"></div></div></div></a></figure></div><p>The “technical capacity” and “diagnostic<a class="footnote-anchor" data-component-name="FootnoteAnchorToDOM" id="footnote-anchor-1" href="#footnote-1" target="_self">1</a> accuracy” of these blood tests are obviously important. But we can imagine what patients are likely to care about: will this test result lead to a better treatment? Will this test result improve my quality of life? We can speculate but we have no idea until we run the trial. </p><p>In the optimistic case you could imagine that rolling out these blood tests in primary care could lead to faster referral to a specialist memory center<a class="footnote-anchor" data-component-name="FootnoteAnchorToDOM" id="footnote-anchor-2" href="#footnote-2" target="_self">2</a> and the initiation of the new anti-amyloid therapies. </p><p>Or this blood test could overly worry the patient or give him or her a devastating diagnosis earlier in their life for no reason or upside. Life lived <strong>not</strong> carrying the “Alzheimer’s Disease” diagnosis should count for a </p>...</source>
      </div>

      <div class="read-full-article">
        <a href="https://synapse.substack.com/p/from-synapse-to-overfitted" class="read-button" target="_blank" rel="noopener">
          Read full article on Synapse &rarr;
        </a>
        <p class="copyright-note">
          This excerpt is provided for preview purposes.
          Full article content is available on the original publication.
        </p>
      </div>
    </article>
  
  </main>
</body>
</html>